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ABSTRACT 
We aimed to evaluate the diagnostic performance of 18F-FDG PET/CT for the detection of post-
transplantation lymphoproliferative disorder (PTLD) in a pediatric population and explore its feasibility 
during response assessment. Methods: This retrospective study included 28 pediatric transplant recipients 
who underwent a total of 32 18F-FDG PET/CT scans due to clinical suspicion of PTLD within an 8-year 
period. Pathology reports and 2-year follow-up were used as reference standard. Twenty-one response 
assessment 18F-FDG PET/CT scans were re-evaluated according to the Lugano criteria. Results: The 
diagnosis of PTLD was established in 14 patients (49%). Sensitivity, specificity, positive predictive value, 
and negative predictive value of 18F-FDG PET/CT for the detection of PTLD in children with a clinical 
suspicion of this disease, was 50% (7/14), 100% (18/18), 100% (7/7), and 72% (18/25), respectively. 
False-negative results occurred in patients with PTLD in the Waldeyer’s ring, cervical lymph nodes or 
small bowel with either non-destructive or polymorphic PTLD. Two of 5 interim 18F-FDG PET/CT scans 
and 3 of 9 end-of-treatment 18F-FDG PET/CT scans were false-positive. Conclusions: 18F-FDG PET/CT 
had good specificity and positive predictive value but low to moderate sensitivity and negative predictive 
value for the detection of PTLD in a 28 pediatric patient cohort with a clinical suspicion of this disease. 
False-negative results were confirmed in the Waldeyer’s ring, cervical lymph nodes and small bowel with 
either non-destructive or polymorphic PTLD subtypes. 18F-FDG PET/CT appears to have a limited role in 
the response assessment setting of pediatric PTLD, given the observed high proportions of false-positives 
both at interim and end-of-treatment evaluations. 
 
Keywords: Post-transplant lymphoproliferative disorder; 18F-fluoro-D-deoxyglucose positron emission 
tomography; 18F-FDG PET/CT; diagnosis; pediatric 
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INTRODUCTION  
Post-transplantation lymphoproliferative disorder (PTLD) is a major complication of continued 
immunosuppressive therapy after solid organ or hematopoietic stem cell transplantation. Morphologically, 
PTLD ranges from Epstein-Barr virus driven polyclonal lesions to aggressive monoclonal lymphoid 
proliferations, classified by the World Health Organization as non-destructive, polymorphic, 
monomorphic or classical Hodgkin lymphoma PTLD (1). 
Compared to adults, pediatric PTLD patients have distinct characteristics regarding incidence and 
presentation. PTLD is the most common post-transplant malignancy in children with higher reported 
incidence than in adults (2–4). An important risk factor associated with PTLD development is Epstein-
Barr virus status mismatch between seropositive donors and seronegative recipients. Epstein-Barr virus 
has a recognized role in the pathogenesis and development of PTLD, particularly related to non-
destructive and polymorphic lesions. Because only 20-25% of the pediatric population is an Epstein-Barr 
virus carrier by the age of 5 (unlike 80-90% in the adult population), children are at an increased risk of 
developing this disorder following transplantation (5,6). Presentation may be asymptomatic or with a 
variation of symptoms including B-symptoms, lymphadenopathy or graft dysfunction. Although it may be 
localized in any organ system, pediatric PTLD has been reported to occur more frequently in the 
Waldeyer’s ring and gastrointestinal tract (7,8). This is in contrast with the adult PTLD population, where 
lesions have been reported to occur proportionally more often in the transplant allograft and lymph nodes 
(6,9).  
Timely diagnosis of PTLD remains challenging, but is crucial for treatment initiation, 
management and prognostication. As reduction of immunosuppression is the first line intervention in 
many PTLD cases, prompt therapy particularly in non-destructive lesions, may be adequate to achieve 
remission. Nevertheless this therapy may also jeopardize the transplanted organ (10–12). Biopsy remains 
necessary for diagnostic confirmation, but imaging may be used to confirm/refute clinical suspicion of 
PTLD and identify suspicious lesions accessible for biopsy. For treatment evaluation, imaging-based 
response assessment may be used to monitor lesions in the entire body, circumventing the need for 
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invasive biopsies with associated complications. 18F-fluoro-2-deoxy-D-glucose (18F-FDG) positron 
emission tomography (PET)/computed tomography (CT) combines metabolic and anatomic information 
and may be of value in the diagnosis and treatment evaluation of pediatric PTLD. Preliminary literature 
suggests that 18F-FDG PET/CT may be helpful in detecting occult lesions and clarifying findings found on 
other imaging modalities (13–19).  However, as these previous studies suffered from small sample sizes 
and frequently mixed children and adults populations, the value of 18F-FDG PET/CT in pediatric PTLD 
remains unclear. If 18F-FDG PET/CT proves accurate in detecting PTLD and feasible for treatment 
evaluation, it may be implemented in future guidelines. In this study we aimed to determine the diagnostic 
performance of 18F-FDG PET/CT for the detection of PTLD in the pediatric population and to explore its 
feasibility in the therapy response assessment setting. 
 
MATERIALS AND METHODS  
Study Design and Patients 
This retrospective single-center study was conducted at the University Medical Center Groningen. 
All consecutive patients ≤18-years-old for whom a 18F-FDG PET/CT scan was requested upon clinical 
suspicion of PTLD between January 2010 until January 2019 were included. The first 18F-FDG PET/CT 
scan and in some children a second/third 18F-FDG PET/CT scan (provided the 18F-FDG PET/CT scan was 
requested because of a clinical suspicion of PTLD, and there was a minimum time interval of 2 years 
without any evidence of PTLD between these scans) were included for the diagnostic performance 
analysis. In patients with pathologically proven PTLD, all 18F-FDG PET/CT scans for treatment 
evaluation were analyzed to explore the feasibility of 18F-FDG PET/CT in the response assessment setting. 
Demographic, relevant clinical data and PTLD morphology/histology were retrieved from the electronic 
patient charts. Patients who had complete tumor resection before 18F-FDG PET/CT and patients in whom 
the established reference standard criteria were not fulfilled were excluded. A waiver was obtained from 
the local medical ethics committee on September 7th 2017 (study number 201700855).  
 
by University of Groningen on February 3, 2020. For personal use only. jnm.snmjournals.org Downloaded from 
18F-FDG PET/CT Acquisition  
All 18F-FDG PET/CT scans were performed on a Siemens Biograph 40- or 64 slice mCT (Siemens 
Healthineers, Erlangen, Germany) according to the “Guidelines for 18F-FDG PET and PET-CT imaging in 
paediatric oncology” from the European Association of Nuclear Medicine (20). The imaging protocol 
included a minimum fasting time of 6 hours. 18F-FDG administration dose was adjusted according to 
weight following European Association of Nuclear Medicine guidelines and 18F-FDG PET/CT scans were 
performed from the mid-thigh to skull base, 60 minutes after intravenous administration. 18F-FDG 
PET/CT images were corrected for scatter and attenuation based on low-dose CT information.  
 
18F-FDG PET/CT for PTLD Detection 
18F-FDG PET/CT scans performed for PTLD detection were retrospectively reviewed by 3 readers 
(2 experienced nuclear medicine physicians (AG and WN) and 1 research fellow (FMJ)) using syngo.via 
software (Siemens Healthineers, Erlangen, Germany). Readers reviewed the scans independently from 
each other and were blinded to other imaging findings, pathology results and clinical findings. Any 
metabolic active focus which could not be related to physiological distribution or any focus with an 18F-
FDG uptake higher than the surrounding tissues, not suggestive of other pathology, was regarded as a 
PTLD-positive 18F-FDG PET/CT scan. If a metabolic active focus was visualized but could not be 
certainly attributed to PTLD or other diseases (such as infectious, inflammatory, or other malignant 
lesions), the 18F-FDG PET/CT scan result was considered ambiguous. A differential diagnosis was noted 
when deemed relevant by the reader. Discordant results between readers were re-evaluated in a consensus 
meeting and conclusively classified as a PTLD-positive 18F-FDG PET/CT or PTLD-negative 18F-FDG 
PET/CT. False-positive and false-negative scans were re-evaluated to determine potential patterns. 
Histopathological examinations were used as a reference standard for PTLD diagnosis. Two experienced 
hematopathologists (SR, AD) were consulted for morphology clarification in 12 patients in whom the 
original pathology report was not sufficiently clear. In the case of a PTLD-negative biopsy or lack of 
tissue for pathological examination, a 2-year follow-up period without pre-emptive PTLD therapy was 
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accepted as the reference standard. In adults, absence of lymphoma during this period has been shown to 
be an accurate marker for lack of disease in other lymphomas (21,22). True-positive scans were those 
interpreted as a PTLD-positive 18F-FDG PET/CT and confirmed by histopathological examination to be 
PTLD within 2 years. True-negative scans were those interpreted as a PTLD-negative 18F-FDG PET/CT 
while no signs of PTLD within a 2-year follow-up were identified. False-positive scans were those 
interpreted as a PTLD-positive 18F-FDG PET/CT while no signs of PTLD within a 2-year follow-up were 
identified. False-negative scans were those interpreted as a PTLD-negative 18F-FDG PET/CT but 
confirmed by histopathological examination to be PTLD within 2 years.  
 
18F-FDG PET/CT for Response Assessment  
All 18F-FDG PET/CT scans performed for response assessment were re-evaluated according to the 
Lugano criteria, while blinded to other imaging findings, pathology results and clinical findings (23). 
Scans with a score of 1-3 were considered indicative of complete remission while scores of 4-5 as partial 
response, stable disease or progressive disease. 18F-FDG PET/CT response assessment scans, for which a 
reference standard was available, were classified as true-positive, true-negative, false-positive, or false-
negative for the presence of PTLD. For interim scans, histopathological examination was accepted as the 
reference standard for PTLD confirmation. For end-of-treatment scans, the accepted reference standard for 
PTLD confirmation was a confirmatory biopsy or high suspicion of death due to PTLD, while a negative 
2-year follow-up period was accepted as confirmation of absence of disease. 
 
Statistical Analysis 
Baseline patient characteristics were summarized using median ± standard deviation with 
interquartile range. Sensitivity, specificity, positive predictive value and negative predictive value of 18F-
FDG PET/CT for the detection of PTLD on a patient-based analysis were calculated with 95% confidence 
interval. Inter-observer variability between the 3 observers was calculated using Fleiss kappa. The kappa 
value was interpreted according to the method of Landis and Koch: poor (0 to 0.20), fair (0.21 to 0.40), 
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moderate (0.41 to 0.60), good (0.61 to 0.80) and perfect agreement (0.81 to 1) (24). Due to the relatively 
small and heterogeneous population, and the inconsistent availability of a reference standard, the 
diagnostic yield of 18F-FDG PET/CT in the response assessment setting for PTLD was only descriptively 





Thirty-three potentially eligible patients were identified. Four patients were excluded as they did 
not fulfill the reference standard criteria (3 did not have a 2-year follow-up and 1 patient received pre-
emptive treatment with rituximab after a negative biopsy). One patient was excluded due to full resection 
of suspected tumor prior to 18F-FDG PET/CT. Because of PTLD suspicion on multiple occasions with a 
time interval of more than 2 years between different 18F-FDG PET/CT scans, 2 patients had 2 eligible 
scans, and 1 patient had 3 eligible scans. Thus, a total of 32 18F-FDG PET/CT scans in 28 patients were 
included. Common indications for requesting an 18F-FDG PET/CT are described in Table 1. There were 
13 (46%) boys and 15 (54%) girls (Table 2). Patient age ranged from 1 to 18 years, with a median age of 4 
years. Liver was the most frequently transplanted organ (n=20, 71.4%), followed by lung (n=3, 10.7%), 
multi-organ (n=2, 7.1%), heart (n=1, 3.6%), kidney (n=1, 3.6%), and small bowel (n=1, 3.6%), According 
to the reference standard, 14 patients (50%) were diagnosed with PTLD, of which 5 (35.7%) non-
destructive, 3 (21.5%) polymorphic, 5 (35.7%) monomorphic, and 1 (7.1%) classical Hodgkin lymphoma 
PTLD. 
 
Diagnostic Performance of 18F-FDG PET/CT for PTLD Detection 
After a consensus meeting by the 3 readers, 7 scans were considered as PTLD-positive and 25 as 
PTLD-negative. A PTLD-positive biopsy, a PTLD-negative biopsy with 2-year follow-up without pre-
emptive therapy, and a 2-year follow-up without pre-emptive therapy nor biopsy were used as reference 
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standard for 14 (43.8%), 10 (31.2%), and 8 (25%) of 18F-FDG PET/CT scans, respectively. According to 
the reference standard, 18 (56.2%) 18F-FDG PET/CT scans were true-negative, 7 (21.9%) true-positive, 0 
false-positive, and 7 (21.9%) false-negative (Table 3). On a patient-based analysis, sensitivity of 18F-FDG 
PET/CT for the detection of PTLD was 50%, specificity 100%, positive predictive value 100% and 
negative predictive value 72% (Table 4). 
Causes of False-negative 18F-FDG PET/CT Scans for PTLD Detection 
Seven of 32 (21.9%) 18F-FDG PET/CT scans performed due to the clinical suspicion of PTLD 
were false-negative (Table 5). Five of 7 false-negative cases had biopsy confirmed non-destructive PTLD. 
On 18F-FDG PET/CT, 3 patients had symmetric 18F-FDG uptake (higher than liver 18F-FDG uptake) in and 
limited to the Waldeyer’s ring, while 2 had symmetric 18F-FDG uptake (higher than liver 18F-FDG uptake) 
in the Waldeyer’s ring along with 18F-FDG-avid (higher than liver 18F-FDG uptake) cervical lymph nodes 
(Fig. 1). The remaining 2 false-negative patients had biopsy confirmed polymorphic PTLD in the small 
intestines, which was interpreted as physiological intestinal 18F-FDG uptake in both cases. In these 2 
patients, no focal 18F-FDG-avid lesions were observed but rather diffuse 18F-FDG uptake (higher than 
liver 18F-FDG uptake) in the gastrointestinal tract. One patient initially had a false-negative scan with 
polymorphic PTLD in the ileum. After adjusting immunosuppression and watchful waiting, the patient 
developed a monomorphic PTLD, which was visualized by subsequent 18F-FDG PET/CT (Fig. 2). 
Abdominal diagnostic CT scan was performed in 1 of these 2 patients, but the clinical radiology report 
mentioned no signs of PTLD. 
 
Inter-observer Variability 18F-FDG PET/CT for PTLD Detection 
From a total of 32 18F-FDG PET/CT scans evaluated prior to consensus meeting, discordant 
results were reported in 5 scans. One 18F-FDG PET/CT scan with symmetric 18F-FDG uptake in the 
Waldeyer’s ring and cervical lymph nodes was considered ambiguous for PTLD by 2 readers, and 
considered interpretable as either reactive lymph nodes or PTLD. One case of 18F-FDG uptake in the 
Waldeyer’s ring and retroperitoneal lymph nodes was also considered to be either due to inflammatory 
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changes or PTLD by 2 readers. In 1 scan with focal 18F-FDG uptake in the lung, 2 out of 3 readers 
reported difficulties in distinguishing between PTLD and an infectious cause (i.e. fungal). Finally, in 1 
scan with localized 18F-FDG uptake in the caecum and in another scan with 18F-FDG uptake throughout 
the whole duodenum and colon, the readers reported difficulties in differentiating if the 18F-FDG uptake 
was physiological, due to PTLD or other intestinal pathology such as colitis. From the 5 discordant 18F-
FDG PET/CT scans: 2 were true-positive, 2 true-negative and 1 false-negative. The remaining 6 false-
negatives scans were reported as PTLD-negative by all readers. The inter-observer variability was found 
to be good at k=0.74 (95% CI: 0.58-0.86).  
 
18F-FDG PET/CT for Response Assessment  
In all 14 patients who were diagnosed with PTLD, reduction of immunosuppression was the 
cornerstone therapy. First-line treatment was carried out with rituximab in 8 patients, R-COP (rituximab, 
cyclophosphamide, vincristine, prednisone) in 2 patients, watchful waiting in 2 patients, R-OEPA 
(rituximab, vincristine, etoposide, prednisone, and doxorubicin) in 1 patient and resection of the tumor in 
1 patient. Two patients were lost to follow-up after diagnosis. 18F-FDG PET/CT was used for interim 
response assessment in 6 patients on 12 occasions, for which biopsy correlation was possible in 5 scans. 
According to pathology, there were 3 true-positive and 2 false-positive interim 18F-FDG PET/CT scans. 
False-positive results were due to therapy induced reactive changes (Fig. 3). End-of-treatment 18F-FDG 
PET/CT was used in 8 patients on 9 occasions and a reference standard was available on all occasions. 
There were, 1 true-positive, 4 true-negative, 3 false-positive and 1 false-negative end-of-treatment 18F-
FDG PET/CT scans. In 2 false-positive cases, a negative 2-year follow-up period did not reveal any PTLD 
and in 1 case, biopsy revealed follicular hyperplasia without evidence of PTLD. For the false-negative 
end-of-treatment 18F-FDG PET/CT, a biopsy obtained 2 months after a PTLD-negative scan revealed 
monomorphic PTLD. 
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DISCUSSION 
This study aimed to evaluate the diagnostic performance of 18F-FDG PET/CT for the detection of 
PTLD in the pediatric population and to explore its feasibility in the response assessment setting. The 
results of the present study suggest that 18F-FDG PET/CT has a good specificity and positive predictive 
value but low to moderate sensitivity and negative predictive value for the detection of PTLD in children, 
especially when disease is localized in the Waldeyer’s ring, cervical lymph nodes or gastrointestinal tract. 
A positive 18F-FDG PET/CT scan may therefore confirm PTLD suspicion, but a negative 18F-FDG 
PET/CT does not rule out PTLD. 
Studies on the clinical utility of 18F-FDG PET/CT in pediatric PTLD are limited and often 
combined with adult PTLD cohorts (13,16,17,19). However, considering the essential differences in 
pathology and presentation of this disease in the two population groups, diagnostic performance analyses 
should be carried out separately for children. To date, studies on pediatric PTLD patients have been 
descriptive in nature, comparing 18F-FDG PET(/CT) to other imaging modalities (such as CT and MRI) on 
a lesion by lesion basis and evaluating how additional detected lesions on 18F-FDG PET(/CT) affected 
staging and treatment (14,15,18,25). Study populations were often small (range: 7 - 34 patients)  and in 2 
out of the 4 previous studies on this topic, stand-alone 18F-FDG PET was used instead of the hybrid 18F-
FDG PET/CT (14,18). Furthermore, a diagnostic performance analysis (in terms of sensitivity, specificity, 
positive predictive value and negative predictive value) for the detection of PTLD was not carried out in 
any of these previous studies.  
While results from mixed and adult cohorts suggest 18F-FDG PET/CT as viable imaging modality 
for PTLD detection at diagnosis (sensitivity 89-85%, specificity 91-89%, positive predictive value 91-
83% and negative predictive value 92-87%), the high number of false-negative cases in our pediatric 
patient population impacted the sensitivity and negative predictive value of 18F-FDG PET/CT for PTLD 
detection (16,26–28). False-negative results in our current study were confirmed in the Waldeyer’s ring 
(n=4), cervical lymph nodes (n=1) and small bowel (n=2) being interpreted as physiological uptake, but 
proven to be either non-destructive or polymorphic PTLD. In pediatric patients particularly, attention 
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should also be paid in the head and neck region. Concerns about false-negative results in the tonsils have 
been previously reported by Vali et al. (18). Non-destructive PTLD tends to occur at a younger age and is 
also often limited to Waldeyer’s ring (1,7). However, uptake in the Waldeyer’s ring is commonly reported 
in children and not necessarily indicative of pathology, leading to potential misinterpretation of uptake in 
this area as physiological (29). Additionally, although reactive 18F-FDG-avid lymph nodes in the cervical 
region are also often reported in children, cervical malignant lymphadenopathy seems to occur more 
frequently in PTLD than in immunocompetent lymphoma patients (30). The gastrointestinal tract is also a 
commonly reported PTLD location in pediatric patients (7,31). Physiological uptake in the gastrointestinal 
tract may obscure or mimic pathology and give rise to false-negative results (32).  
Despite low to moderate sensitivity and negative predictive value for the detection of PTLD at 
diagnosis, 18F-FDG PET/CT retains clinical utility in the management of pediatric PTLD patients. Due to 
the high number of false-negative scans in the tonsils/adenoids, physicians must remain alert for signs that 
might indicate the presence of disease, such as high Epstein-Barr virus DNA load and tonsillar 
hypertrophy (4,33). Nevertheless, if a biopsy is positive for non-destructive PTLD in the tonsils/adenoids 
but the 18F-FDG PET/CT is interpreted as PTLD-negative, it may indicate that the disease is focal and 
therapy may be limited to reduction of immunosuppression (or potentially rituximab) and clinical follow-
up. With regard to uptake in the gastrointestinal tract, one study has demonstrated that patient preparation 
with of N-butylscopolamine (buscopan) reduces artifacts in the bowel and improves accuracy (34). 
Furthermore, CT has also been suggested as a more sensitive modality for PTLD lesion detection in bowel 
and stomach (18). Patient specific preparation and an abdominal diagnostic CT scan may be necessary in a 
selected group of patients if lower gastrointestinal tract PTLD is suspected. The high specificity and 
positive predictive value of 18F-FDG PET/CT in the disease detection setting are clinically relevant as 
concerns about false-positives 18F-FDG PET/CT scans, predominately due to inflammation or other 
malignancies, are often encountered in the literature (26,35). However, compared to adults, the risk of a 
malignancy (other than PTLD) is decreased in pediatric transplant patients, which may explain the lack of 
false-positive scans in the disease detection setting in this study (36).  
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Regarding the potential contribution of 18F-FDG PET/CT during treatment evaluation in pediatric 
PTLD, there were 40% (2/5) false-positive interim 18F-FDG PET/CT scans. For end-of-treatment 18F-FDG 
PET/CT, there were 33% (3/9) false-positive and 11% (1/9) false-negative scans. Interim false-positive 
results were predominantly due to therapy induced reactive changes. This is in line with a systematic 
review by Adams et al. in immunocompetent lymphoma patients, in which concerns about high 
proportions of false-positive were raised, reporting false-positive results in 55.7% of all 18F-FDG-avid 
lesions that were biopsied during and at end-of-treatment (the majority due to inflammatory changes) (37). 
The retrospective nature of this study constitutes a significant limitation. Important variables such 
a patient selection and timing of 18F-FDG PET/CT could not be controlled. As there are currently no 
guidelines on the use 18F-FDG PET/CT for the diagnosis of PTLD in pediatric patients, each medical 
department defined their own criteria to request a scan. Previous examinations performed before 18F-FDG 
PET/CT in the included patients, may have influenced a priori incidence of PTLD and therefore diagnostic 
performance. In addition to potentially inducing selection bias, the lack of control on patient management 
variables may also have affected 18F-FDG PET/CT diagnostic performance during treatment evaluation. 
Taking into consideration the lack of literature and the limitations of retrospective studies, future research 
on this topic should focus on prospective and multi-center studies. 
 
CONCLUSION 
18F-FDG PET/CT showed good specificity and positive predictive value but low to moderate 
sensitivity and negative predictive value for the detection of PTLD in a 28 pediatric patient cohort  with 
clinical suspicion of this disease. False-negative results were confirmed in the Waldeyer’s ring, cervical 
lymph nodes or small bowel with either non-destructive or polymorphic PTLD subtypes. 18F-FDG 
PET/CT appears to have a limited role in the response assessment setting of pediatric PTLD, given the 
observed high proportions of false-positives both at interim and end-of-treatment evaluations. 
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KEY POINTS 
QUESTION: Is 18F-FDG PET/CT an accurate imaging modality for PTLD detection in pediatric patients 
with suspicion of the disorder? 
PERTINENT FINDINGS: In this single-center retrospective study, including a total of 28 patients and 32 
scans, sensitivity, specificity, positive predictive value, and negative predictive value of 18F-FDG PET/CT 
for the detection of PTLD in children with a clinical suspicion of this disease, was 50% (7/14), 100% 
(18/18), 100% (7/7), and 72% (18/25), respectively. False-negative results were confirmed in the 
Waldeyer’s ring, cervical lymph nodes and small bowel with either non-destructive or polymorphic PTLD 
subtypes. 
IMPLICATIONS FOR PATIENT CARE: Clinicians should be aware of 18F-FDG PET/CT inherent 
limitations, paying particular attention to potential focus of disease in the Waldeyer’s ring, cervical lymph 
nodes and gastrointestinal tract of pediatric patients.  
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Figure 1. Two-year-old boy 1 year after liver transplant because of biliary atresia. 18F-FDG PET/CT 
requested after prolonged fever. False-negative 18F-FDG PET/CT scan with biopsy confirmed non-
destructive PTLD in the adenoid/tonsils. Maximum intensity projection 18F-FDG PET (A) shows an 
almost symmetrical uptake in the Waldeyer’s ring and salivary glands. Axial fused 18F-FDG PET/CT (B) 
shows almost symmetrical uptake in the adenoids. This pattern of 18F-FDG uptake was interpreted as 
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Figure 2. Three-year-old girl 2 months after small bowel transplant because of an unexplained absorption 
disorder. 18F-FDG PET/CT requested during clinical admission due to fever and leucopenia. False-
negative 18F-FDG PET/CT scan with biopsy confirmed polymorphic PTLD in the ileum (A, B, E). 
Maximum intensity projection 18F-FDG PET (A) and axial fused 18F-FDG PET/CT (B) show diffuse 
uptake in the small bowel (white arrow) interpreted as physiological uptake. On low-dose CT (E), 
distended gas-filled bowels and post-operative ileostomy are shown. Same patient 6 months after 
reduction in immunosuppression and watchful waiting (C, D, F). True-positive 18F-FDG PET/CT scan 
with biopsy confirmed monomorphic intestinal PTLD. Maximum intensity projection 18F-FDG PET (C) 
shows multiple intrapulmonary, mesenteric and intestinal 18F-FDG-active lesions. Axial fused 18F-FDG 
PET/CT (D) shows focal 18F-FDG uptake in the small bowel suspicious for PTLD without evident 
abnormalities on low-dose CT (F).  
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Figure 3. Three-year-old boy 2 years after liver transplant because of biliary atresia. 18F-FDG PET/CT 
requested after 3x R-COP therapy. False-positive interim 18F-FDG PET/CT scan confirmed after biopsy 
via colonoscopy revealed therapy induced reactive changes in the caecum. Maximum intensity projection 
18F-FDG PET (A) and axial fused 18F-FDG PET/CT (B) show an 18F-FDG-avid lesion in the caecum 
(white arrow). On diagnostic CT (C) a spherical mass is seen in the caecum (white arrow). 100x 
magnification with hematoxylin and eosin staining (D) shows lymphoid infiltration without abnormal cells 
(black arrow). 
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FIGURES AND TABLES 
Table 1. Indications for 18F-FDG PET/CT* 
 No. 
Blood panel disturbances 
(e.g. complete blood count, biochemistry) 7 (21.9%) 
EBV DNAemia 19 (59.4%) 
Physical symptoms 
(e.g. B-symptoms, enlarged lymph nodes) 
13 (40.6%) 
After previous examinations  
Colonoscopy 4 (12.5%) 
Conventional radiography 1 (3.1%) 
CT 2 (6.3%) 
EBV - Epstein-Barr virus  




Table 2. Patient Characteristics (n=28) 





Male 13 (46%) 
Female 15 (54%) 
Transplanted organ  
Liver 20 (71.4%) 
Lung 3 (10.7%) 
Multi-organ 2 (7.1%) 
Heart 1 (3.6%) 
Kidney 1 (3.6%) 
Small Bowel 1 (3.6%) 
Histology  
Non-destructive 5 (35.7%) 
Polymorphic 3 (21.5%) 
Monomorphic 5 (35.7%) 
Classical Hodgkin lymphoma  1 (7.1%) 
IQR - Interquartile range 
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7 (21.9%) 0  
18F-FDG PET/CT 
negative 




Table 4. Diagnostic Performance of 18F-FDG PET/CT in PTLD Detection  
Analysis Value % 95% CI 
Sensitivity  50 24-76 
Specificity 100 78-100 
Positive predictive value 100 56-100 
Negative predictive value 72 50-87 
CI - Confidence interval  
 
 
Table 5. Description of False-negative 18F-FDG PET/CT Scans 




Waldeyer’s ring Physiological uptake Non-destructive PTLD  
Waldeyer’s ring Physiological uptake Non-destructive PTLD  
Waldeyer’s ring Physiological uptake Non-destructive PTLD  
Waldeyer’s ring Physiological uptake Non-destructive PTLD 
Cervical lymph node 
Physiological uptake 
Reactive lymph nodes 
PTLD 
Non-destructive PTLD  
Duodenum, mesenteric 
lymph nodes 
Physiological uptake Polymorphic PTLD  
Ileum Physiological uptake Polymorphic PTLD 
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